Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

NCT02276612 PHASE2, PHASE3 COMPLETED Results posted

The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to \< 18 years of age.

Details

Lead sponsor	Gilead Sciences
Phase	PHASE2, PHASE3
Status	COMPLETED
Enrolment	60
Start date	Wed Dec 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Oct 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• HIV

Interventions

• E/C/F/TAF

Countries

South Africa, United States